Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS

v3.2.0.727
RELATED PARTY TRANSACTIONS
 6 Months Ended
Jun. 30, 2015
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]
9.  RELATED PARTY TRANSACTIONS
 
The Company’s chief scientific officer and principal founder of Cellectar, who is a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”).  During the six months ended June 30, 2015, the Company was invoiced $417,813 by UW, of which $415,613 has been paid, for costs associated with clinical trial agreements.